Actigraphy Sensors and PSG Devices Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Actigraphy Sensors and PSG Devices Market is segmented By Product Type (Actigraphy Sensors, Polysomnography Devices) By Application (Sleep Monitoring, Fitness Monitoring, Disease Monitoring, Clinical Research, Others) By Configuration (Wristband, Neck and head bands, Sensor Caps, Others) By End-User (Hospitals and Clinics, Homecare, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Actigraphy Sensors and PSG Devices Market reached US$ 1.35 billion in 2023 and is expected to reach US$ 2.03 billion by 2031, growing at a CAGR of 5.30% during the forecast period 2024-2031.

Actigraphy sensors are portable and non-invasive devices used to track the sleep-wake patterns of individuals. They are more commonly used in home and non-clinical settings. Actigraphy plays a vital role in diagnosing various sleep disorders like insomnia, circadian rhythm sleep-wake disorders, sleep apnea, and insufficient sleep syndrome. 

PSG devices are used in clinical settings for the diagnosis and treatment of sleep disorders. They provide more comprehensive data on sleep stages, breathing patterns, and other physiological parameters.

Actigraphy Sensors and PSG Devices Market Scope

For more details on this report – Request for Sample

Actigraphy Sensors and PSG Devices Market Dynamics: Drivers & Restraints

Rise in the prevalence of sleep disorders

The rising prevalence of sleep disorders, such as insomnia, sleep apnea, and restless legs syndrome, is a major driver of the actigraphy sensors and PSG devices market. As awareness about these conditions grows and their impact on overall health becomes more evident, there is a greater demand for diagnostic tools to monitor and manage sleep patterns effectively.

For instance, according to the American Psychiatric Association, about one-third of adults report some insomnia symptoms, 10 to 15% report problems with functioning during the daytime and 4 to 22% have symptoms severe enough to meet the criteria for insomnia disorder. An estimated 40 to 50% of individuals with insomnia also have another mental disorder.

Challenges associated with the devices

The most important challenges are the development of nonintrusive hardware implementation, smart signal processing, data analysis and interpretation, communication standards interoperability, electronic component efficiency, energy self-sufficiency, and long-term monitoring.

Actigraphy Sensors and PSG Devices Market Segment Analysis

The global actigraphy sensors and PSG devices market is segmented based on product type, application, configuration end-user and region.

The actigraphy sensors from the product type segment accounted for approximately 51.3% of the Actigraphy sensors and PSG devices  market share

The actigraphy sensors from the product type segment accounted for approximately 51.3%. Actigraphy is indicated for determining the sleep-wake patterns of patients with insomnia and circadian rhythm disorders and for determining the response to therapy in patients with circadian rhythm disorders. Studies of actigraphy have usually compared the results with those of PSG or sleep logs.

Actigraphy sensors are expected to have a high market share due to novel product launches, increased COVID-19 infections, awareness, and relaxation of restrictions in industrialized countries. Demand for these devices is expected to grow due to increased awareness of sleep deprivation treatments, product availability, and advanced public sector healthcare facilities and organizations.

For instance, in November 2023, ActiGraph, a leader in wearable digital health technology and digital health sciences for clinical drug development and academic research, introduced its next-generation multisensor wearable, the ActiGraph LEAP.

Moreover, in April 2023, Empatica, a digital health and AI company developing medical-grade wearables and digital biomarkers for health monitoring and diagnostics, announced the launch of Empatica Actigraphy, a powerful new addition to the company's FDA-cleared Empatica Health Monitoring Platform, offering a new set of digital biomarkers for monitoring sleep and physical activity along with the capability to collect data continuously for up to 14 days on a single charge.

Actigraphy Sensors and PSG Devices Market Geographical Analysis

North America is estimated to hold about 42.4% of the total market share throughout the forecast period

North America is estimated to hold about 42.4% of the total market share throughout the forecast period owing to factors like novel product launches by companies, FDA approvals, the rising geriatric population, the high prevalence of chronic sleep disorders, the efficiency and affordability of the industry with the technological breakthroughs, as well as the presence of established research institutions.

For instance, in March 2024, Beacon Biosignals announced that it had received FDA 510(k) clearance for SleepStageML, an advanced machine learning software that automatically stages sleep from electroencephalogram (EEG) signals of clinical polysomnography (PSG) recordings to aid in the diagnosis and evaluation of sleep and sleep-related disorders. 

Covid 19 Impact Analysis On Actigraphy Sensors and PSG Devices Market

The COVID-19 pandemic has significantly disrupted the actigraphy sensors and PSG devices market, leading to increased demand for products like telehealth, remote testing, and data monitoring. This has led to increased interest in remote diagnostic and data monitoring technology, particularly in disposable home sleep apnea testing devices. This has accelerated the use of wearables and AI/ML/DL integrations, enhancing the quality of sleep care.

Actigraphy Sensors and PSG Devices Market Competitive Landscape

The major global players in the market include Koninklijke Philips N.V., Neurocare Group, Cadwell Laboratories Inc., SOMNOmedics GmbH, ActiGraph LLC, Advanced Brain Monitoring Inc., Nox Medical, BMC, Cidelec, Compumedics among others.

Key Developments

• In April 2022, Onera Health received the US Food and Drug Administration clearance for their non-invasive patch-based clinical-grade compact medical device for polysomnography, Onera STSI, designed to diagnose sleep disorders in patients in hospitals, sleep laboratories, or home settings.
• In March 2020,  Nox Medical officially launched its innovative polysomnographic system, the Nox A1, in the U.S. and Canada. The Nox A1 is a powerful, ambulatory PSG device that combines thoughtful design with clinical accuracy, allowing sleep labs to maximize their investment with multiple functions in one single device.

Why Purchase the Report?

• To visualize the global actigraphy sensors and PSG devices market segmentation based on product type, application, configuration, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development. 
• excel data sheet with numerous data points of the actigraphy sensors and PSG devices market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global actigraphy sensors and PSG devices market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies